Agomab Therapeutics (AGMB) said Thursday that it priced its initial public offering of 12.5 million American depositary shares at $16 per ADS, for total proceeds of $200 million.
The company granted the underwriters a 30-day option to acquire up to about 1.9 million ADSs.
Agomab expects to close the IPO on Feb. 9 and said its ADSs are set to start trading on the Nasdaq Global Select Market on Friday under the ticker "AGMB."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.